DR. GABRIEL RAE HELEN SCHROEDER MD
Prescription History 1265964621
Internal Medicine - Pulmonary Disease in Saint Louis, MO


Quality Rating: 79.29 out of 100 score

NPI Status: Active since April 03, 2017

Contact Information

1 BARNES JEWISH HOSPITAL PLZ
DIV IM PULMONARY
SAINT LOUIS, MO
ZIP 63110
Phone: (314) 454-8762
Fax: (314) 454-7524

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. GABRIEL RAE HELEN SCHROEDER MD, an active Pulmonary Disease specialist practicing in Saint Louis, MO. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 83 documented patient claims. Among these therapy options, the most frequently utilized medication is Ofev, which accounts for 25 claims alone.

Medication Index

No matching medications currently found on file.

Anoro Ellipta

Generic Formulation: Umeclidinium Brm/Vilanterol TrSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 22
30-Day Fills 24.0
Days Supply 720
MO State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills42.5
Peer Average Days Supply1,267
Conservative Utilization

This provider writes prescriptions for this formulation 37.1% less frequently than the standard regional baseline metric for practitioners inside MO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $11,779.42 across this reporting matrix range.

Provider Avg Cost Per Claim

$535.43

State Avg Cost Per Claim

$568.49

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: umeclidinium and vilanterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Vilanterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Umeclidinium/vilanterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as vilanterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Mycophenolate Mofetil

Generic Formulation: Mycophenolate MofetilSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 18
30-Day Fills 21.0
Days Supply 614
MO State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills50.4
Peer Average Days Supply1,480
Conservative Utilization

This provider writes prescriptions for this formulation 40.0% less frequently than the standard regional baseline metric for practitioners inside MO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,412.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$78.48

State Avg Cost Per Claim

$131.24

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.

Therapeutic Applications

Mycophenolate is used in combination with other medications to keep your body from attacking and rejecting your transplanted organ (such as kidney, liver, heart). It belongs to a class of medications called immunosuppressants. It works by weakening your body's defense system (immune system) to help your body accept the new organ as if it were your own.

Ofev

Generic Formulation: Nintedanib EsylateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 25
30-Day Fills 25.0
Days Supply 750
MO State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills33.2
Peer Average Days Supply992
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $349,882.69 across this reporting matrix range.

Provider Avg Cost Per Claim

$13,995.31

State Avg Cost Per Claim

$12,517.41

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of lung disease (idiopathic pulmonary fibrosis- IPF, interstitial lung disease). Both types of lung disease scar and stiffen your lungs, making it hard to breathe. Nintedanib may help slow down the worsening of your lung disease.

Prednisone

Generic Formulation: PrednisoneSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 18
30-Day Fills 22.0
Days Supply 458
MO State Average Benchmarks
Peer Average Claims51.0
Peer Average 30-Day Fills61.5
Peer Average Days Supply1,100
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 64.7% less volume than the regional standard for practitioners inside MO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $87.74 across this reporting matrix range.

Provider Avg Cost Per Claim

$4.87

State Avg Cost Per Claim

$6.02

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. GABRIEL RAE HELEN SCHROEDER MD provides transparency into local medical care patterns within Saint Louis, MO.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Pulmonary Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.